We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

137 hedge funds and large institutions have $522M invested in Aerie Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

208% more call options, than puts

Call options by funds: $3.27M | Put options by funds: $1.06M

37% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 38

4% less funds holding

Funds holding: 142 → 137 (-5)

18% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 22

28% less capital invested

Capital invested by funds: $727M → $522M (-$205M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
137
Holders Change
-5
Holders Change %
-3.52%
% of All Funds
2.4%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
18
Increased
52
Reduced
38
Closed
22
Calls
$3.27M
Puts
$1.06M
Net Calls
+$2.21M
Net Calls Change
+$2.26M

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$31.4M
2
William Blair Investment Management
William Blair Investment Management
Illinois
+$10.1M
3
Citadel Advisors
Citadel Advisors
Florida
+$8.7M
4
Morgan Stanley
Morgan Stanley
New York
+$5.2M
5
Walleye Capital
Walleye Capital
New York
+$3.99M

Top Sellers

Rank Fund Capital Flow
1
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$30M
2
WP
Woodline Partners
California
-$6.71M
3
Principal Financial Group
Principal Financial Group
Iowa
-$6.7M
4
ACM
Atika Capital Management
New York
-$6.33M
5
Two Sigma Investments
Two Sigma Investments
New York
-$2.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
GIP
26
Granite Investment Partners
California
$4.68M +$1.62M +110,675 +37%
FCM
27
Frontier Capital Management
Massachusetts
$4.55M -$158K -10,776 -3%
N
28
Nuveen
North Carolina
$4.26M -$801K -54,778 -13%
Renaissance Technologies
29
Renaissance Technologies
New York
$3.67M -$668K -45,663 -12%
NAM
30
Nexpoint Asset Management
Texas
$3.53M – – –
Charles Schwab
31
Charles Schwab
California
$3.39M -$267K -18,267 -6%
DCM
32
DAFNA Capital Management
California
$3.29M – – –
AGA
33
Altrinsic Global Advisors
Connecticut
$3.08M +$439K +30,000 +13%
Balyasny Asset Management
34
Balyasny Asset Management
Illinois
$3M +$3.84M +262,835 New
IHAM
35
Integral Health Asset Management
New York
$2.85M -$2.34M -160,000 -39%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$2.69M -$822K -56,200 -19%
Goldman Sachs
37
Goldman Sachs
New York
$2.45M -$269K -18,415 -8%
EWM
38
Endurance Wealth Management
Rhode Island
$2.34M +$404K +27,611 +16%
Norges Bank
39
Norges Bank
Norway
$2.3M +$2.18M +148,981 +283%
VOYA Investment Management
40
VOYA Investment Management
Georgia
$2.29M -$151K -10,341 -5%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$2.28M +$158K +10,793 +6%
JAMONY
42
Jacob Asset Management of New York
California
$2.2M +$938K +64,166 +50%
Fidelity Investments
43
Fidelity Investments
Massachusetts
$2.12M -$512 -35 -0%
HA
44
Homestead Advisers
Virginia
$1.78M +$61.4K +4,200 +3%
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$1.66M +$1.02M +69,842 +93%
SG Americas Securities
46
SG Americas Securities
New York
$1.59M +$636K +43,527 +45%
DA
47
DCF Advisers
Connecticut
$1.56M +$661K +45,201 +50%
Allianz Asset Management
48
Allianz Asset Management
Germany
$1.55M – – –
Millennium Management
49
Millennium Management
New York
$1.46M -$1.15M -78,784 -38%
PPA
50
Parametric Portfolio Associates
Washington
$1.36M +$91.7K +6,276 +6%
1
2
3 4 5

AERI Hedge Fund Activity: Q3 2021 in Review

137 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2021, worth a combined $522M — down 28% from $727M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of AERI and 18 opened new positions — a net loss of 4 holders — while 38 trimmed existing stakes and 52 added.

The largest buyer was Deerfield Management, adding an estimated $31.4M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $30M sold.

  • 137 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2021, down from 142 in Q2 2021.
  • Funds reported $522M of Aerie Pharmaceuticals stock for Q3 2021, down 28% quarter-over-quarter.
  • 18 funds opened new Aerie Pharmaceuticals positions in Q3 2021 and 22 closed out, a net change of -4 holders.
  • The largest Aerie Pharmaceuticals buyer in Q3 2021 was Deerfield Management, an estimated $31.4M added.
  • The largest Aerie Pharmaceuticals seller in Q3 2021 was Loomis, Sayles & Company, an estimated $30M sold.

Based on aggregated 13F filings for Q3 2021.